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Summary
Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated 
interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive 
and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill 
burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The eﬃ  cacy 
and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus 
peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection.
Methods In QUEST-1, a phase 3, randomised, double-blind multicentre trial undertaken in 13 countries (Australia, 
Europe, North America, Puerto Rico, and New Zealand), 394 patients (aged ≥18 years) with chronic HCV genotype 1 
infection and no history of HCV treatment, stratiﬁ ed by HCV subtype and host IL28B genotype, were randomly 
assigned in a 2:1 ratio with a computer-generated allocation sequence to receive simeprevir (150 mg once daily, orally) 
plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir 
group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus 
ribavirin (placebo group). Treatment duration was 24 weeks or 48 weeks in the simeprevir group according to criteria 
for response-guided therapy (ie, HCV RNA <25 IU/mL [undetectable or detectable] at week 4 and <25 IU/mL 
undetectable at week 12) and 48 weeks in the placebo group. Patients, study personnel, and the sponsor were masked 
to the treatment group assignment. The primary eﬃ  cacy endpoint was sustained virological response 12 weeks after 
the planned end of treatment (SVR12) and was assessed with an intention-to-treat analysis. The results of the primary 
analysis (week 60) are presented for safety and SVR12. This trial is registered with ClinicalTrials.gov, number 
NCT01289782.
Findings Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to placebo, peginterferon 
alfa 2a, and ribavirin (SVR12 in 210 [80%] patients of 264 vs 65 [50%] of 130, respectively, adjusted diﬀ erence 29·3% 
[95% CI 20·1–38·6; p<0·0001). Adverse events in the ﬁ rst 12 weeks of treatment led to discontinuation of simeprevir 
in two (<1%) patients and discontinuation of placebo in one patient (<1%); fatigue (106 [40%] vs 49 [38%] patients, 
respectively) and headache (81 [31%] vs 48 [37%], respectively) were the most common adverse events. The prevalences 
of anaemia (42 [16%] vs 14 [11%], respectively) and rash (72 [27%] vs 33 [25%]) were similar in the simeprevir and 
placebo groups. Addition of simeprevir did not increase severity of patient-reported fatigue and functioning 
limitations, but shortened their duration.
Interpretation Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naive 
patients with HCV genotype 1 infection without worsening the adverse event proﬁ les associated with peginterferon 
alfa 2a plus ribavirin.
Funding Janssen Infectious Diseases–Diagnostics.
Introduction
Infection with hepatitis C virus (HCV) is one of the 
leading causes of liver failure worldwide, and resulted in 
195 000 deaths in 2010.1 Every year, 3–4 million 
individuals become infected with the virus; about 
150 million chronically infected patients are at risk of 
developing liver cirrhosis or liver cancer.2,3
For many years, the standard of care for HCV infection 
was a combination of pegylated interferon (peginterferon) 
alfa plus ribavirin. However, 50–60% of patients infected 
with HCV genotype 1 did not have a sustained virological 
response (SVR) with peginterferon alfa and ribavirin.4
The addition of the HCV NS3/4A protease inhibitors 
boceprevir and telaprevir to peginterferon alfa plus 
ribavirin combination regimens has improved SVR in 
treatment-naive and treatment-experienced patients 
infected with HCV genotype 1, allowing some individuals 
to have a reduction in the duration of treatment.5–9 
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However, treatment with these agents is limited by 
increased rates and severity of adverse events, such as 
anaemia and rash, and challenging dosing schedules 
with a high pill burden.10–13
Simeprevir (TMC435; Janssen and Medivir) is a one 
pill, once daily, oral HCV NS3/4A protease inhibitor that 
has been approved in Japan, Canada, the USA, Russia, 
and Europe for the treatment of patients with chronic 
HCV infection. Similar to other HCV NS3/4A protease 
inhibitors, simeprevir acts by inhibiting the protease-
mediated cleavage of several of the non-structural 
proteins of HCV from the polypeptide encoded by 
the viral genome.14 Simeprevir has broad genotypic 
coverage, with antiviral activity against HCV 
genotypes 1, 2, and 4–6.15,16 In phase 2a and 2b trials, 
simeprevir, at a dose of 150 mg for 12 weeks, had potent 
eﬃ  cacy and a favourable safety proﬁ le in both treatment-
naive and treatment-experienced patients with HCV 
genotype 1 infection.16–19
We investigated the eﬃ  cacy, safety, and tolerability of 
simeprevir in combination with peginterferon alfa plus 
ribavirin in treatment-naive patients with HCV genotype 1 
infection in the phase 3 QUEST-1 trial. Our aim in this trial 
was to conﬁ rm the safety proﬁ le and superior eﬃ  cacy of 
simeprevir in combination with peginterferon alfa 2a plus 
ribavirin compared with just peginterferon alfa 2a plus 
ribavirin, which was the standard treatment for infection 
with HCV genotype 1 at the time of initiation of QUEST-1. 
We present the data from the primary analysis (at week 60) 
of the ﬁ nal results of the primary endpoint.
Methods
Patients and study design
QUEST-1 was a multicentre, randomised, double-blind, 
parallel-group, placebo-controlled, phase 3 clinical trial to 
assess the eﬃ  cacy, safety, and tolerability of simeprevir in 
combination with peginterferon alfa plus ribavirin 
(simeprevir group) versus placebo in combination with 
peginterferon alfa plus ribavirin (placebo group) in 
treatment-naive patients with HCV genotype 1 infection. 
In the trial, we also included patient self-assessments of 
symptoms commonly associated with existing HCV 
treatments, and routine functioning and health-related 
quality of life. Overall treatment duration in the 
simeprevir group was either 24 weeks or 48 weeks 
according to the response-guided therapy criteria 
(including 12 weeks of dosing with simeprevir), whereas 
patients in the control group received placebo plus 
peginterferon alfa plus ribavirin for 48 weeks. The trial 
was done between Jan 18, 2011, and Jan 29, 2013, at 
71 sites in 13 countries (Australia, Canada, Germany, 
Italy, Mexico, New Zealand, Puerto Rico, Romania, 
Russia, Spain, Ukraine, the UK, and the USA).
Eligible patients were aged 18 years and older with 
conﬁ rmed chronic HCV genotype 1 infection, screening 
plasma HCV RNA concentration greater than 
10 000 IU/mL, and no history of treatment for HCV 
infection. Patients with cirrhosis were eligible if an 
ultrasound within the previous 6 months showed no 
signs of hepatocellular carcinoma.
Exclusion criteria included hepatic decompensation or 
any non-HCV-related liver disease; co-infection with 
HIV, hepatitis B virus, or non-genotype 1 HCV infection; 
signiﬁ cant laboratory abnormalities; any other active 
disease; and male or female patients who had, or were 
planning to conceive.
Institutional review boards of all participating 
institutions approved the study. Written informed 
consent was obtained from all participants according to 
local regulations.
Patients received simeprevir (150 mg once daily, orally) or 
placebo orally in combination with peginterferon alfa 2a 
(180 μg/week, subcutaneously) plus ribavirin (1000 mg/day 
or 1200 mg/day, orally, depending on bodyweight [<75 kg or 
≥75 kg, respectively]). Patients in the simeprevir group 
received simeprevir plus peginterferon alfa 2a plus ribavirin 
for 12 weeks, followed by peginterferon alfa 2a plus 
ribavirin without simeprevir for 12 weeks or 36 weeks. 
According to criteria for response-guided therapy, treatment 
was stopped at week 24 if HCV RNA was less than 
25 IU/mL (undetectable or detectable) at week 4 and less 
than 25 IU/mL undetectable at week 12 or continued with 
peginterferon alfa 2a plus ribavirin until week 48. Patients 
in the placebo group received placebo plus peginterferon 
alfa 2a plus ribavirin for the ﬁ rst 12 weeks, followed by 
peginterferon alfa 2a plus ribavirin for 36 weeks. All 
patients in the placebo group continued this combination 
until week 48. Patients in both groups were followed up for 
up to 72 weeks after the start of treatment (appendix p 3).
In accordance with the virological stopping rules, 
simeprevir or placebo was discontinued if HCV RNA 
concentration was greater than 1000 IU/mL at week 4, 
whereas the peginterferon alfa 2a plus ribavirin 
combination was continued. Peginterferon alfa 2a plus 
ribavirin was discontinued if a reduction of smaller than 
2 log10 IU/mL in HCV RNA from baseline was detected at 
week 12, or if HCV RNA was conﬁ rmed to be at least 
25 IU/mL at week 24 or week 36.
Randomisation and masking
After stratiﬁ cation according to HCV genotype 1 subtype 
(1a, 1b, or other) and IL28B genotype (SNP rs12979860; 
CC, CT, or TT) to optimise the balance between treatment 
groups, patients were randomly assigned to the 
simeprevir or placebo group in a 2:1 ratio. We used a 
computer-generated randomisation schedule prepared 
by or under the supervision of the sponsor before the 
study, balanced using randomly permuted blocks, and 
implemented using an interactive web-based or voice-
response system. This interactive web-based or voice-
response system assigned a unique code that dictated the 
treatment assignment and matching study drug kit for 
each patient. The patients, study personnel, and the 
sponsor were masked to the treatment group assignment. 
See Online for appendix
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The randomisation codes were maintained within the 
interactive web-based or voice-response system. HCV 
RNA levels were monitored by an external person who 
was not masked and was responsible for informing the 
investigators of any required changes to treatment.
Procedures
Blood samples were obtained at screening, 
days 1, 7, 14, and 28, every 4 weeks thereafter until 
week 28, and at weeks 36, and 48 for those receiving 
24 weeks of treatment and at weeks 36, 42, 48 and 52 for 
those continuing treatment until week 48.
HCV RNA was then measured using the HCV/High 
Pure System assay (version 2.0, Roche COBAS TaqMan, 
Pleasanton, CA, USA; lower limit of quantiﬁ cation 
25 IU/mL and limit of detection 15 IU/mL). In patients 
who discontinued study medication early, HCV RNA 
measurements were obtained at the time of withdrawal, 
during the 4 weeks after withdrawal, and every 12 weeks 
until week 72.
Standard population sequencing to assess for resistant 
variants of the HCV NS3/4A protease domain of HCV 
was done on baseline samples and those from patients in 
whom treatment failed at selected timepoints (based on 
HCV RNA changes and sensitivity limit of the sequencing 
assay). IL28B genotyping was done on blood samples 
obtained at screening.
Adverse events were monitored throughout the trial. 
Blood samples for biochemical and haematological 
analyses were obtained at screening and during scheduled 
visits. Electrocardiogram, vital sign assessment, and 
physical examination were also done at scheduled visits.
We gathered data for fatigue and productivity (including 
activity impairment and absenteeism) using the Fatigue 
Severity Score (FSS)20 and the Work Productivity and 
Activity Impairment questionnaire for hepatitis C 
(WPAI)21 at baseline and throughout the study. The 
Centre for Epidemiologic Studies Depression Scale 
(CES-D)22 questionnaire was used to assess the eﬀ ect of 
treatment on depression, with data gathered at baseline 
and all the way through the study. Perceived health status 
and quality of life at baseline and during treatment were 
assessed through the EuroQol 5-dimension questionnaire 
(EQ-5D).23 The ﬁ ve health dimensions measured with the 
EQ-5D were mobility, self-care, usual activities, pain or 
discomfort, and anxiety or depression.
Outcomes
The primary eﬃ  cacy endpoint was the proportion of 
patients achieving SVR12, deﬁ ned as HCV RNA 
concentration of less than 25 IU/mL undetectable at end 
of treatment and less than 25 IU/mL detectable or 
undetectable 12 weeks after the planned end of treatment. 
The secondary endpoints were comparison of SVR 
24 weeks after the planned end of treatment (SVR24); 
percentage of patients meeting criteria for response-
guided therapy to complete treatment at week 24; rapid 
virological response (RVR), deﬁ ned as HCV RNA less 
than 25 IU/mL undetectable at week 4; on-treatment 
failure, deﬁ ned as conﬁ rmed detectable HCV at end of 
treatment; incidence of viral breakthrough, deﬁ ned as 
HCV RNA increase of more than 1 log10 IU/mL from the 
lowest level noted or an HCV RNA concentration more 
than 100 IU/mL when previously less than 25 IU/mL, or 
viral relapse (presence of HCV RNA ≥25 IU/mL during 
follow-up or at the time of SVR assessments after 
achieving undetectable levels at the end of the treatment); 
incidence of adverse events and laboratory abnormalities; 
and patient-reported symptoms and functioning. We also 
assessed polymorphisms at baseline and their correlation 
with simeprevir eﬃ  cacy. We also report data for the eﬀ ect 
of baseline characteristics on treatment response and 
data from assessment of depression severity, and health 
status. Data were also gathered for the following 
endpoints, but are not reported because they were not 
available at the time of this analysis or the endpoints 
were not within the scope of this report: SVR at week 72, 
pharmacokinetics of simeprevir or the relation between 
simeprevir pharmacokinetics and eﬃ  cacy or safety, 
gathering of data for medical resource use, and the eﬀ ect 
of CYP3A4, CYP2C19, and drug transporter genotypes 
on pharmacokinetics, treatment response, and selected 
safety endpoints.
A total of three amendments were made to the trial 
protocol, on Nov 10, 2010, May 26, 2011, and Dec 14, 
2011. In the ﬁ rst amendment, the primary eﬃ  cacy 
Figure 1: Trial proﬁ le
Patients in the simeprevir group received simeprevir, pegylated interferon alfa 2a, and ribavirin; patients in the 
placebo group received placebo, pegylated interferon alfa 2a, and ribavirin.
481 patients screened 
395 randomly assigned
28 completed treatment
92 on treatment at 
primary analysis
62 completed treatment
181 on treatment at 
primary analysis
394 treated
1 did not receive treatment
because of signiﬁcant 
comorbidities
86 screening failures because did
not meet inclusion criteria or 
met exclusion criteria
130 placebo group264 simeprevir  group
10 discontinued study
1 withdrew consent
1 non-compliance
2 other
6 lost to follow-up 
21 discontinued study
8 withdrew consent
2 non-compliance
1 sponsor’s decision
1 other
9 lost to follow-up 
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endpoint was changed from the percentage of patients 
with SVR at week 60 to the percentage of patients with 
SVR24. In the second amendment, the sponsor clariﬁ ed 
the guidelines for the unmasking of patients to ensure 
that those in whom treatment failed had alternative 
treatment options or were rolled over into the TMC435-
TiDP16-C213 (ClinicalTrials.gov identiﬁ er NCT01323244) 
study without delay if needed. This protocol amendment 
also allowed for the use of methadone. In the third 
amendment, because of the strong correlation shown 
descriptively between SVR12 and SVR24 in simeprevir 
phase 2b studies (PILLAR19 and ASPIRE17), and in phase 
3 trials of telaprevir7 and boceprevir,8 and in agreement 
with health authorities, the primary endpoint was 
changed from SVR24 to SVR12 and SVR24 was changed 
to a secondary endpoint. No change in sample size was 
judged to be necessary to achieve statistical power for 
the trial because of the strong correlation between 
SVR12 and SVR24.
Statistical analysis
SGS Life Sciences Services (Mechelen, Belgium) did the 
statistical analyses using SAS (version 9.1). According to 
the null hypothesis, there was no signiﬁ cant diﬀ erence 
between the active treatment (simeprevir plus 
peginterferon alfa 2a plus ribavirin) and the control 
treatment (placebo plus peginterferon alfa 2a plus 
ribavirin) for the primary eﬃ  cacy endpoint (SVR12). We 
used the 5% signiﬁ cance level for the comparison of 
treatment groups for the primary eﬃ  cacy endpoint. 
Because SVR12 in the control group was estimated to be 
45%,24,25 at 5% signiﬁ cance (two-sided p value), with 
125 patients in the control group and 250 in the 
simeprevir group, the power to detect a signiﬁ cant 
diﬀ erence of at least 20% between the two treatment 
groups was expected to be greater than 90%.
Patients’ baseline demographics and disease 
characteristics were summarised descriptively. For the 
primary endpoint, we compared SVR rates in the 
simeprevir and placebo groups using the Cochran-
Mantel-Haenszel test adjusted for the stratiﬁ cation 
factors. Additionally, a 95% CI was calculated for the 
response rate in each treatment group. As a sensitivity 
analysis, the SVR12 in the simeprevir group was 
compared with that in the placebo group with a logistic 
regression model including baseline HCV RNA 
(log10 IU/mL, included as a continuous variable) and the 
stratiﬁ cation factors HCV genotype 1 subtype and IL28B 
genotype. The 95% CI for the diﬀ erence in the 
percentages of patients in the two groups who had 
SVR12 was calculated according to this model. For 
secondary eﬃ  cacy response measures, 95% CIs were 
calculated for response rates and for the diﬀ erence in 
response rates between groups.
All analyses were done on the intention-to-treat 
population, deﬁ ned as patients who received at least one 
dose of investigational drug (simeprevir or placebo). 
According to the statistical analysis plan, if the 
percentage of patients with a major protocol deviation 
was less than or equal to 10% there was no need for a 
per-protocol analysis of the primary endpoint based on 
data from all patients in the intention-to-treat population 
with exclusion of patients with a major protocol 
deviation. Further details about the statistical analyses 
are provided in the appendix.
This trial is registered with ClinicalTrials.gov, number 
NCT01289782.
Role of the funding source
The funder of the study designed the trial, analysed, and 
interpreted the data, and helped write and review the 
Simeprevir group
(n=264)
Placebo group (n=130)
Women 116 (44%) 56 (43%)
Age (years; median, IQR) 48 (39–54) 48 (36–54)
Ethnic origin
White 227 (86%) 122 (94%)
Black or African-American 27 (10%) 4 (3%)
Asian 5 (2%) 3 (2%)
BMI (kg/m²; median, range) 26·6 (16·5–45·2) 26·7 (17·0–53·5)
HCV subtype (NS5B)
1a 147 (56%) 74 (57%)
1b 117 (44%) 56 (43%)
Baseline HCV RNA concentration >800 000 IU/mL 218 (83%) 96 (74%)
HCV with baseline Q80K* 61 (23%) 30 (23%)
HCV subtype 1a* 60 (41%) 30 (41%)
HCV subtype 1b* 1 (<1%) 0
METAVIR score26
F0–F1 118 (45%) 50 (38%)
F2 65 (25%) 40 (31%)
F3 46 (17%) 23 (18%)
F4 31 (12%) 17 (13%)
IL28B genotype
CC 77 (29%) 37 (28%)
CT 150 (57%) 76 (58%)
TT 37 (14%) 17 (13%)
FSS n=263 n=130
Mean (SE) 3·5 (0·10) 3·3 (0·13)
WPAI Productivity score n=259 n=128
Mean (SE) 18·7 (1·59) 19·2 (2·09)
WPAI Daily Activity Impairment score n=259 n=128
Mean (SE) 18·6 (1·60) 18·5 (2·08)
WPAI Absenteeism n=128 n=71
Mean (SE) 3·6 (1·29) 6·1 (2·18)
Data are number (%), unless otherwise indicated. Patients in the simeprevir group received simeprevir, pegylated 
interferon alfa 2a, and ribavirin; patients in the placebo group received placebo, pegylated interferon alfa 2a, and 
ribavirin. BMI=body-mass index. HCV=hepatitis C virus. FSS=Fatigue Severity Score. WPAI=Work Productivity and Activity 
Impairment: hepatitis C questionnaire. *Patients for whom sequencing data were available: 262 of 264 patients in the 
simeprevir group overall, 129 of 130 in the placebo group overall, 146 of 147 in the simeprevir group HCV subtype 1a, 
73 of 74 in the placebo group HCV subtype 1a, 116 of 117 in the simeprevir group HCV subtype 1b, and all 56 in the 
placebo group HCV subtype 1b.
Table 1: Baseline characteristics of patients
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report. All authors had full access to all the data in the 
study and are responsible for the completeness of the 
data. All the authors had ﬁ nal responsibility for the 
decision to submit for publication.
Results
395 (82%) of 481 patients who were screened were 
randomly assigned to treatment. 394 patients who were 
randomly assigned to treatment received at least one dose 
of study drug (264 in the simeprevir group and 130 in the 
placebo group; ﬁ gure 1). Major protocol deviations were 
reported in nine (3%) of 264 patients in the simeprevir 
group and ﬁ ve (4%) of 130 in the placebo group.
Similar numbers of patients were enrolled from 
Europe and North America (Canada, Mexico, Puerto 
Rico, and the USA), and baseline characteristics were 
generally similar between the treatment groups (table 1), 
except for a higher proportion of black or African-
American patients in the simeprevir group versus 
placebo group (10% vs 3%, respectively).
SVR12 was achieved in a higher percentage of patients 
in the simeprevir group than in the placebo group 
(80% vs 50%), and the diﬀ erence stratiﬁ ed by HCV 
genotype 1 subtype and IL28B genotype was signiﬁ cant 
(29·3%, 95% CI 20·1–38·6; p<0·0001; table 2). RVR 
was higher in the simeprevir group than in the placebo 
group (80% vs 12%; table 2). In the simeprevir group, 
181 (90%) of 202 patients with RVR achieved SVR12.
A higher proportion of patients in the simeprevir group 
had SVR24 than in the placebo group (205 [83%] of 247 vs 
18 [60%] of 30; weighted diﬀ erence 18·1%, 95% CI –0·4 
to 36·6; p=0·0253). At the time of the primary analysis, 
SVR24 data were available for 247 patients in the 
simeprevir group and 30 in the placebo group. These 
ﬁ ndings are in line with SVR12 data.
Most of the patients in the simeprevir group (85%) met 
criteria for response-guided therapy to complete 
treatment at week 24 (table 3). Of these patients, 91% 
subsequently achieved SVR12 (table 3). 21% of the 
patients who did not meet the criteria for response-guided 
treatment achieved SVR12 (table 3). 73% of the patients 
who met the criteria had undetectable HCV RNA at 
week 4 and 92% of these patients achieved SVR12 
(table 3). Of the 28 patients meeting the criteria for 
response-guided treatment but with HCV RNA less than 
25 IU/mL detectable at week 4, 79% subsequently 
achieved SVR12 (table 3). 12 (5%) of 264 patients 
discontinued treatment before the assessment for 
response-guided therapy. Two patients did not have a 
week 4 HCV RNA result. However, based on other 
measurements, these patients were judged to meet 
criteria for response-guided therapy, and therefore were 
included in the met criteria for response-guided therapy, 
but were excluded from the week 4 subanalysis.
Figure 2 shows the subpopulation analyses. Baseline 
HCV RNA, HCV genotype (1a or 1b), METAVIR26 score 
(F0–F2, F3, or F4), and IL28B genotype (CC, CT, or TT) 
had an eﬀ ect on SVR12; however, the rates were 
consistently higher in the simeprevir group than in the 
placebo group and most diﬀ erences were signiﬁ cant 
(table 4). Sex did not have an eﬀ ect on SVR12 in the 
simeprevir group (ﬁ gure 2). Q80K is a naturally occurring 
NS3 polymorphism that confers low-level resistance to 
simeprevir (7·7 times change in 50% maximal eﬀ ective 
concentration as a single aminoacid substitution in a 
genotype 1b replicon).26 The presence of the Q80K 
polymorphism at baseline in patients infected with HCV 
genotype 1a given simeprevir was associated with a lower 
SVR12 than in patients without this polymorphism at 
baseline (table 4). 38 (63%) of 60 simeprevir-treated 
patients infected with HCV genotype 1a with the Q80K 
polymorphism at baseline achieved RVR and 28 (74%) of 
these 38 patients achieved SVR12. 64 (74%) of 86 patients 
infected with HCV genotype 1a without the Q80K 
polymorphism at baseline achieved RVR with simeprevir, 
and 59 (92%) of these 64 achieved SVR12. 99 (85%) of 
117 patients with HCV genotype 1b in the simeprevir group 
Simeprevir  group 
(n=264)
Placebo group 
(n=130)
Diﬀ erence (95% CI)
Week 4
<25 IU/mL undetectable (RVR) 202/254 (80%) 15/127 (12%) 68·0 (60·5 to 75·4)
<25 IU/mL undetectable or detectable 230/254 (91%) 25/127 (20%) 70·3 (62·4 to 78·1)
SVR12 210/264 (80%) 65/130 (50%) 29·3 (20·1 to 38·6)
On-treatment failure* 24 (9%) 44 (34%) –24·9 (–33·7 to –16·0)
Met virological stopping rule at week 
12, 24, or 36
14 (5%) 36 (28%) –23·2 (–31·7 to –14·8)
Viral relapse† 21/234 (9%)‡ 18/84 (21%) –12·5 (–22·1 to –3·0)
Data are n/N (%) or number (%), unless otherwise indicated. Patients in the simeprevir group received simeprevir, 
pegylated interferon alfa 2a, and ribavirin; patients in the placebo group received placebo, pegylated interferon alfa 2a, and 
ribavirin. RVR=rapid virological response. SVR12=sustained virological response at 12 weeks deﬁ ned as an undetectable 
HCV RNA concentration (<25 IU/mL undetectable) at the end of treatment and HCV RNA less than 25 IU/ml detectable or 
undetectable at 12 weeks after the planned end of treatment. HCV=hepatitis C virus. The denominators for the SVR12 data 
are the number of patients in the intention-to-treat population per treatment group; the week 4 response data are for the 
on-treatment virological response. *HCV RNA was conﬁ rmed to be detectable at end of treatment. †Patients with 
undetectable HCV RNA at the end of treatment. ‡Viral relapse occurred within 12 weeks of the end of treatment in 
20 patients in the simeprevir group and in 16 patients in the placebo group. Relapse occurred after week 12 of follow-up 
but before the SVR12 assessment in one simeprevir-treated patient, who prematurely discontinued treatment with all 
study drugs because of non-compliance.
Table 2: Virological response over time (RVR and SVR12), and on-treatment failure and relapse, according 
to treatment group in the intention-to-treat population
Simeprevir group (n=264) SVR12
Met criteria for response-guided treatment* 224/264 (85%) 203/224 (91%)
HCV RNA <25 IU/mL (undetectable) at week 4 194/264 (73%) 179/194 (92%)
HCV RNA <25 IU/mL (detectable) at week 4 28/264 (11%) 22/28 (79%)
Did not meet criteria for response-guided treatment 28/264 (11%) 6/28 (21%)
Data are n/N (%). Patients in the simeprevir group received simeprevir, pegylated interferon alfa 2a, and ribavirin. 
*12 patients could not be classiﬁ ed in accordance with the criteria for response-guided treatment and discontinued 
study treatment before the assessment of their eligibility—ie, they discontinued before the HCV measurement at week 
4, or they discontinued before measurement at week 12 if they had HCV RNA concentration less than 25 IU/mL 
detectable or undetectable at week 4.
Table 3: Proportion of patients meeting criteria for response-guided treatment in the simeprevir, 
peginterferon alfa 2a and ribavirin group and corresponding SVR12 in the intention-to-treat population
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had RVR and 93 (94%) of these 99 patients achieved SVR12. 
59 (22%) of 264 patients in the simeprevir group had dose 
reductions in ribavirin compared with 30 (23%) of 130 in 
the placebo group. SVR12 values were similar in the 
simeprevir group irrespective of whether or not the patients 
had a dose reduction in ribavirin (50 [85%] of 59 and 
160 [78%] of 205, respectively). 17 (63%) of 27 black or 
African-American patients in the simeprevir group 
achieved SVR12 compared with one (25%) of four in the 
placebo group. 16 (59%) of 27 black or African-American 
patients treated with simeprevir had RVR and 15 (94%) of 
these individuals achieved SVR12.
On-treatment failure (ie, detectable HCV RNA at end of 
treatment) was noted in 9% of patients in the simeprevir 
group and 34% in the placebo group (table 2). A lower 
percentage of patients in the simeprevir group met the 
virological stopping rule requiring discontinuation of all 
treatment at week 12, 24, or 36, than in the placebo group 
(5% vs 28%, respectively; table 2). Similarly, a lower 
percentage of patients in the simeprevir group met the 
virological stopping rule at week 4 (ie, cessation of 
simeprevir or placebo and continuation of peginterferon 
alfa 2a plus ribavirin) than in the placebo group (12 [5%] 
of 264 vs 83 [64%] of 130, respectively). Viral relapse was 
less common in the simeprevir group than in the placebo 
group (9% vs 21%, respectively; table 2), and occurred 
within 12 weeks of the end of treatment in 20 (95%) of 
21 patients with relapse in the simeprevir group and 
16 (89%) of 18 in the placebo group.
Figure 2: Diﬀ erence in SVR12 between treatment groups by demographic and baseline characteristics of patients
Data are n/N, unless otherwise indicated. Patients in the simeprevir group received simeprevir, pegylated interferon alfa 2a, and ribavirin; patients in the placebo group 
received placebo, pegylated interferon alfa 2a, and ribavirin. SVR12=sustained virological response at 12 weeks deﬁ ned as HCV RNA undetectable (<25 IU/mL 
undetectable) at the end of treatment and HCV RNA less than 25 IU/mL detectable or undetectable 12 weeks after the planned end of treatment. HCV=hepatitis C virus.
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72/77
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152/183
36/46
18/31
Placebo group
25/34
40/96
36/74
29/56
36/74
16/30
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29/56
29/37
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4/17
54/90
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5/17
Diﬀerence (95% CI)
19·6% (9·2 to 30·1)
38·2% (26·7 to 49·7)
34·7% (23·6 to 45·9)
34·5% (22·9 to 46·0)
28·2% (13·4 to 42·9)
1·3% (–23·7 to 26·3)
44·6% (26·5 to 62·6)
42·1% (26·5 to 57·6)
14·8% (6·4 to 23·2)
38·0% (26·7 to 49·2)
38·8% (28·1 to 49·5)
31·1% (20·3 to 41·9)
40·6% (28·9 to 52·3)
40·7% (29·5 to 51·8)
Baseline HCV RNA concentration (IU/mL)
Sex
≤800 000 
>800 000 
HCV genotype
1a
1b
IL28B genotype
CC
CT
TT
METAVIR score
F0–F2
F3
1a with baseline Q80K
Male
Female
F4
1a without baseline Q80K
–50 0 50 100–100
Favours placebo (%) Favours simeprevir (%) 
Simeprevir group 
(n=264)
Placebo group 
(n=130)
Diﬀ erence (95% CI) p value
HCV subtype
1a 105/147 (71%) 36/74 (49%) 28·2 (13·4 to 42·9) 0·0002
With baseline Q80K 31/60 (52%) 16/30 (53%) 1·3 (–23·7 to 26·3) 0·9199
Without baseline Q80K 73/86 (85%) 19/43 (44%) 44·6 (26·5 to 62·6) <0·0001
1b 105/117 (90%) 29/56 (52%) 42·1 (26·5 to 57·6) <0·0001
METAVIR score
F0–F2 152/183 (83%) 54/90 (60%) 31·1 (20·3 to 41·9) <0·0001
F3–F4 54/77 (70%) 11/40 (28%) 40·9 (29·5 to 52·2) <0·0001
F3 36/46 (78%) 6/23 (26%) 40·6 (28·9 to 52·3) <0·0001
F4 18/31 (58%) 5/17 (29%) 40·7 (29·5 to 51·8) <0·0001
IL28B genotype
CC 72/77 (94%) 29/37 (78%) 14·8 (6·4 to 23·2) 0·0006
CT 114/150 (76%) 32/76 (42%) 38·0 (26·7 to 49·2) <0·0001
TT 24/37 (65%) 4/17 (24%) 38·8 (28·1 to 49·5) <0·0001
Baseline HCV RNA concentration (IU/mL)
≤800 000 42/46 (91%) 25/34 (74%) 19·6 (9·2 to 30·1) 0·0003
>800 000 168/218 (77%) 40/96 (42%) 38·2 (26·7 to 49·7) <0·0001
Sex
Male 117/148 (79%) 36/74 (49%) 34·7 (23·6 to 45·9) <0·0001
Female 93/116 (80%) 29/56 (52%) 34·5 (22·9 to 46·0) <0·0001
Data are n/N (%), unless otherwise indicated. Patients in the simeprevir group received simeprevir, pegylated 
interferon alfa 2a, and ribavirin; patients in the placebo group received placebo, pegylated interferon alfa 2a, and 
ribavirin. HCV=hepatitis C virus. SVR12=sustained virological response at 12 weeks deﬁ ned as HCV RNA less than 
<25 IU/mL undetectable at the end of treatment and HCV RNA less than 25 IU/mL detectable or undetectable 12 weeks 
after the planned end of treatment.
Table 4: SVR12 according to HCV genotype, METAVIR score, IL28B genotype, baseline HCV RNA, and sex
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Data for paired baseline sequencing and treatment 
failure in patients treated with simeprevir who did not 
achieve SVR12 showed emergent mutations at the time 
of failure in 35 (92%) of 38 patients for whom sequencing 
data were available. For patients infected with genotype 
1a, these emergent mutations were mainly R155K alone 
or with other aminoacid substitutions at positions 80 or 168 
(the six NS3 positions of interest are 43, 80, 122, 155, 156, 
and 168). For patients infected with genotype 1b, the 
mutations were mainly D168V.
Overall frequencies of adverse events were similar in 
the two groups during the ﬁ rst 12 weeks of treatment and 
for the entire treatment (table 5). In the ﬁ rst 12 weeks of 
treatment, grade 3 adverse events were reported in 20% 
versus 26% of patients, grade 4 adverse events in 
3% versus 3% of patients, and serious adverse events 
in 3% versus 4% of patients in the simeprevir and 
placebo groups, respectively. The adverse events resulted 
in less than 1% of patients permanently discontinuing 
simeprevir or placebo in the ﬁ rst 12 weeks and during 
the entire treatment period. In the ﬁ rst 12 weeks, 3% of 
patients in the simeprevir group discontinued all study 
drugs compared with 2% in the placebo group. No deaths 
occurred during the trial. Fatigue and headache were the 
most common adverse events in the simeprevir and 
placebo groups, occurring in more than 25% of patients 
(table 5).
Adverse events of clinical interest in the ﬁ rst 12 weeks of 
treatment were pruritus in 24% and 13% of patients in the 
simeprevir and placebo groups, respectively; most cases of 
pruritus were grade 1 or 2 and occurred early in treatment, 
with rare discontinuations of study drugs (table 5). Rash 
(any type) during the ﬁ rst 12 weeks occurred with a similar 
frequency in both groups (simeprevir 27% and placebo 
First 12 weeks Entire treatment
Simeprevir group 
(n=264)
Placebo  group 
(n=130)
Simeprevir  group
(n=264)
Placebo  group 
(n=130)
Any adverse event 250 (95%) 123 (95%) 255 (97%) 125 (96%)
Most frequently reported adverse events*
Fatigue 106 (40%) 49 (38%) 110 (42%) 53 (41%)
Headache 81 (31%) 48 (37%) 88 (33%) 51 (39%)
Grade 1 or 2 adverse events 189 (72%) 85 (65%) 181 (69%) 75 (58%)
Grade 3 adverse events 54 (20%) 34 (26%) 65 (25%) 43 (33%)
Grade 4 adverse events 7 (3%) 4 (3%) 9 (3%) 7 (5%)
Serious adverse events 7 (3%) 5 (4%) 10 (4%) 8 (6%)
Adverse events leading to permanent discontinuation 
of simeprevir or placebo
2 (<1%)† 1 (<1%) 2 (<1%) 1 (<1%)
Adverse events leading to permanent 
discontinuation of all study drugs
7 (3%)‡ 3 (2%) 7 (3%) 3 (2%)
Adverse events of special interest
Increased bilirubin§ 24 (9%) 5 (4%) 24 (9%) 6 (5%)
Grade 1 or 2 17 (6%) 3 (2%) 17 (6%) 3 (2%)
Grade 3 6 (2%) 2 (2%) 6 (2%) 2 (2%)
Grade 4 1 (<1%) 0 1 (<1%) 0
Leading to permanent stop¶ 1 (<1%)|| 0 1 (<1% )|| 0
Adverse events of clinical interest
Rash (any type)** 72 (27%) 33 (25%) 89 (34%) 42 (32%)
Grade 1 or 2 70 (27%) 33 (25%) 87 (33%) 42 (32%)
Grade 3 2 (<1%) 0 2 (<1%) 0
Grade 4 0 0 0 0
Leading to permanent stop¶ 4 (2%) 1 (<1%) 4 (2%) 1 (<1%)
Pruritus†† 63 (24%) 17 (13%) 79 (30%) 26 (20%)
Grade 1 or 2 62 (23%) 17 (13%) 77 (29%) 26 (20%)
Grade 3 1 (<1%) 0 2 (<1%) 0
Grade 4 0 0 0 0
Leading to permanent stop¶ 1 (<1%) 0 2 (<1%) 0
Photosensitivity reactions 7 (3%) 1 (<1%) 7 (3%) 1 (<1%)
Grade 1 or 2 7 (3%) 1 (<1% ) 7 (3%) 1 (<1% )
Grade 3 or 4 0 0 0 0
Leading to permanent stop¶ 0 0 0 0
(Table 5 continues on next page)
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25%) and was mostly grade 1 or 2, with the exception of 
grade 3 rash in less than 1% of patients treated with 
simeprevir (table 5). Treatment (with at least one study 
drug) was discontinued due to rash in 2% and less than 
1% of patients who received simeprevir and placebo, 
respectively (table 5).
Mean concentrations of haemoglobin were similar in 
the two treatment groups until week 24; thereafter, 
haemoglobin concentrations in the simeprevir group 
returned to baseline levels (appendix p 4). Most 
reductions in haemoglobin concentrations were of 
grade 1 or 2 (table 5).
19% of patients in the simeprevir group had neutropenia 
during the ﬁ rst 12 weeks of treatment compared with 11% 
in the placebo group, but the incidences of grade 3 and 4 
neutropenia were similar in both groups (9% and 2% with 
simeprevir, respectively, and 7% and zero with placebo, 
respectively; table 5). No occurrences of neutropenia were 
serious (table 5).
Mild, transient increases in bilirubin were noted in the 
simeprevir group in the ﬁ rst 12 weeks of treatment, with 
2% of patients having a grade 3 bilirubin increase and 
less than 1% a grade 4 increase (table 5). Bilirubin 
increases were rapidly reversible after the end of 
simeprevir dosing (appendix p 4) and mainly attributable 
to increases in indirect (unconjugated) bilirubin. 
Increased bilirubin concentration was an adverse event 
in 9% of patients in the simeprevir group in the ﬁ rst 
12 weeks of treatment compared with 4% of those in the 
placebo group (table 5). Only one patient discontinued 
treatment due to increased bilirubin concentration in the 
simeprevir group (table 5). This patient did not have any 
increase in transaminases, and simeprevir was stopped 
according to a protocol-deﬁ ned toxicity management 
guideline. Increases in alanine aminotransferase and 
aspartate aminotransferase were infrequent and similar 
between the treatment groups, and were not associated 
with increased bilirubin (data not shown).
Patient-reported fatigue severity, impairment in 
productivity, and daily activity impairment scores 
increased (worsened) by similar amounts in both 
treatment groups from baseline to week 4 and remained 
increased in both groups until the end of week 24 
(appendix p 5). Scores returned to values that were 
similar to baseline between weeks 24 and 36 in the 
simeprevir group and weeks 48 and 60 in the placebo 
group (appendix p 5). According to a piecewise linear 
mixed model, scores for fatigue (p=0·0008), productivity 
impairment (p=0·0296), and daily activity impairment 
(p=0·0097) were signiﬁ cantly lower in patients who 
received simeprevir than in those who received placebo, 
in agreement with the shorter treatment duration in the 
First 12 weeks Entire treatment
Simeprevir group 
(n=264)
Placebo  group 
(n=130)
Simeprevir  group 
(n=264)
Placebo  group 
(n=130)
(Continued from previous page)
Neutropenia 49 (19%) 14 (11%) 64 (24%) 23 (18%)
Grade 1 or 2 21 (8%) 5 (4%) 26 (10%) 7 (5%)
Grade 3 23 (9%) 9 (7%) 32 (12%) 15 (12%)
Grade 4 5 (2%) 0 6 (2%) 1 (<1%)
Leading to permanent stop¶ 0 0 0 1 (<1% )
Haemoglobin decrease (any grade) 67 (25%) 34 (26%) 98 (37%) 58 (45%)
Grade 1 48 (18%) 26 (20%) 68 (26%) 37 (28%)
Grade 2 16 (6%) 5 (4%) 26 (10%) 17 (13%)
Grade 3 3 (1%) 3 (2%) 4 (2%) 4 (3%)
Grade 4 0 0 0 0
Anaemia (any grade) 42 (16%) 14 (11%) 53 (20%) 27 (21%)
Grade 1 or 2 40 (15%) 10 (8%) 51 (19%) 22 (17%)
Grade 3 2 (<1%) 3 (2%) 2 (<1%) 4 (3%)
Grade 4 0 1 (<1%) 0 1 (<1%)
Leading to permanent stop¶ 0 2 (2%) 1 (<1%) 2 (2%)
Data are number (%), unless otherwise indicated. Patients in the simeprevir group received simeprevir, peginterferon alfa 2a, and ribavirin; patients in the placebo group received 
placebo, peginterferon alfa 2a, and ribavirin. A comparison of the frequency of adverse events in the ﬁ rst 12 weeks in patients who received treatment with simeprevir, 
peginterferon alfa 2a, and ribavirin with patients who received peginterferon alfa 2a plus ribavirin (with or without placebo) shows any toxicities related to simeprevir. The 
investigators graded the adverse events, and information about the severity grading of adverse events is provided in the appendix p 2. Peginterferon=pegylated interferon. 
MedDRA=Medical Dictionary for Regulatory Activities. *In more than 25% of patients during the ﬁ rst 12 weeks of treatment and during the entire treatment period in the 
simeprevir group. †Adverse events in these two patients were rash and increased bilirubin concentration in the blood. ‡Adverse events in these seven patients were major 
depression, overdose, psoriasis, positive pregnancy test, rash, rash and skin burning sensation, or rash and pruritus. §Increased bilirubin concentration included MedDRA 
preferred terms . ¶Permanent cessation of at least one study drug. ||Grade 2 jaundice. **Rash MedDRA high-level terms: erythemas; papulosquamous disorders; rashes, 
eruptions, and exanthemas not elsewhere classiﬁ ed; photosensitivity conditions; standardised MedDRA query severe cutaneous adverse reaction: narrow scope and selected 
terms of the broad scope. ††Pruritus included MedDRA high-level term pruritus not classiﬁ ed elsewhere.
Table 5: Summary of adverse events during the ﬁ rst 12 weeks and during the entire treatment
For the MedDRA preferred terms 
see http://www.meddra.org/
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simeprevir group (appendix p 5). Diﬀ erences in terms of 
absenteeism between the two treatment groups were not 
signiﬁ cant (appendix p 5).
Mean CES-D scores for depression severity were 
similar at baseline in both groups (appendix p 6). During 
the ﬁ rst 24 weeks of treatment, mean CES-D scores were 
increased compared with baseline in both groups 
(indicating increased symptoms of depression), but 
were slightly lower in patients in the placebo group than 
in the simeprevir group (appendix p 6). Between 
weeks 36 and 48, mean CES-D scores in the patients in 
the simeprevir group fell and remained at baseline 
values throughout follow-up, whereas those in the 
placebo group remained increased until the end of 
week 48, returning to baseline values at week 60 
(appendix p 6). Similar trends were captured with the 
EQ-5D questionnaire (data not shown).
Discussion
In this trial, a signiﬁ cantly higher percentage of 
treatment-naive patients with chronic hepatitis C virus 
genotype 1 infection who were receiving simeprevir in 
combination with peginterferon alfa 2a and ribavirin 
(simeprevir group) achieved SVR12 (primary eﬃ  cacy 
endpoint) than did those receiving placebo in 
combination with peginterferon alfa 2a and ribavirin 
(placebo group), and had lower on-treatment failure and 
relapse rates. 85% of patients in the simeprevir group 
met criteria for response-guided therapy and were 
eligible to complete treatment at week 24, and 91% of 
these subsequently achieved SVR12 (table 2).
Reduction of the overall treatment duration is beneﬁ cial 
for several reasons, including a shorter mean exposure to 
peginterferon alfa and ribavirin, thus leading to a reduced 
frequency of adverse events related to peginterferon alfa 
and ribavirin, reduction in costs, and improvements in 
quality-adjusted life-years.28,29 An additional advantage is 
that once-daily, oral dosing of simeprevir is a simpliﬁ ed, 
easy-to-adhere-to regimen for patients (panel).
In QUEST-1, patients in the simeprevir group had a 
signiﬁ cantly higher on-treatment virological response 
than did those in the placebo group, with 80% achieving 
RVR (HCV RNA <25 IU/mL undetectable at week 4; 
table 2), and 91% achieving SVR with 24 weeks of 
treatment. Of the patients who met the criteria for 
response-guided treatment, we noted higher SVR12 in 
patients with HCV RNA of less than 25 IU/mL 
undetectable at week 4 than in those with HCV RNA less 
than 25 IU/mL detectable (table 3).
In patients treated with peginterferon alfa plus ribavirin, 
HCV genotype 1a,30 IL28B non-CC genotype,31 and 
cirrhosis or advanced ﬁ brosis32,33 are associated with lower 
SVR rates. These classic baseline predictors of response 
also have an eﬀ ect on SVR rates in patients treated with 
simeprevir in combination with peginterferon alfa 2a 
plus ribavirin. However, in QUEST-1, SVR12 in the 
simeprevir group was signiﬁ cantly higher than in the 
placebo group, irrespective of IL28B genotype (CC, CT, or 
TT), HCV genotype (1a or 1b), or METAVIR score (F0–F4). 
In terms of the IL28B genotype, the highest SVR12 was 
noted in patients in the simeprevir group with the CC 
genotype (94%; table 4), although the diﬀ erence in SVR12 
between patients with this genotype and those without 
this genotype was substantially smaller than in the 
placebo group, indicating that there is a weaker correlation 
between IL28B genotype and eﬃ  cacy of simeprevir than 
the association with just peginterferon alfa plus ribavirin.34 
Simeprevir also resulted in higher SVR12 in patients with 
cirrhosis (F4) than did placebo. SVR12 frequencies in the 
simeprevir group were similar in patients with HCV 
genotype 1a without the Q80K polymorphism at baseline 
and with genotype 1b. However, in patients with HCV 
genotype 1a who had the Q80K polymorphism at baseline 
(a factor that does not aﬀ ect the response to peginterferon 
alfa 2a plus ribavirin), SVR12 was not signiﬁ cantly higher 
with simeprevir than with placebo (table 4). Most patients 
treated with simeprevir who did not achieve SVR12 had 
emergent mutations at the time of failure; these 
mutations were similar to those previously reported with 
simeprevir.27
Generally, the safety and tolerability proﬁ le of simeprevir 
was similar to that established for peginterferon alfa plus 
ribavirin regimens. The reported adverse events in the 
simeprevir group were clinically manageable, and most 
were grade 1 or 2. A lower percentage of patients in the 
simeprevir group discontinued treatment than did those 
in the placebo group, and this diﬀ erence might be 
attributable to the shorter treatment duration in the 
simeprevir group. Treatment with simeprevir did not lead 
to an increased incidence of rash or anaemia, as noted 
with other protease inhibitors.5,7,8,10,11,13,35,36 Unlike with 
telaprevir and boceprevir, mean reductions in 
haemoglobin concentrations were similar between the 
simeprevir and placebo groups during the study and they 
were matched by similar patterns and degree of anaemia 
(a study of the comparison of simeprevir with telaprevir 
is in progress). Of note, rash (seen with telaprevir) 
seldom led to discontinuation of treatment. Simeprevir 
was associated with increases in bilirubin concentrations; 
however, these increases were mild and transient and 
were not associated with concomitant increases in other 
laboratory markers of liver function. Simeprevir-
associated bilirubin increases are mainly driven by 
increases in unconjugated bilirubin because it is an 
inhibitor of organic anion transporting polypeptide 1B1 
and multidrug resistance protein 2 in vitro.37
Severity of patient-reported fatigue, productivity impair-
ment, and impairment in daily activities were signiﬁ cantly 
reduced overall in the simeprevir group compared with the 
placebo group. Mean scores for patient-reported depressive 
symptom severity (CES-D) and overall quality of life (EQ-
5D) worsened to similar degrees in each group after 
patients started treatment, and remained at those levels for 
the duration of treatment with peginterferon alfa 2a plus 
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ribavirin (up to week 24 in the simeprevir group, and up to 
week 48 in the placebo group). This pattern was consistent 
with that noted with fatigue, productivity, and activity 
impairment. The shortened duration of simeprevir-based 
treatment from 48 weeks to 24 weeks reduces the adverse 
eﬀ ect of greater fatigue, lower productivity, and more 
protracted depression associated with traditional interferon 
treatment.
A limitation of our study was that recruitment was 
largely in North America and Europe (175 [44%] and 166 
[42%] of 394 patients, respectively), thus potentially 
reducing the applicability of the results to other 
geographical regions. Other limitations were that most of 
the patients were white, with a small proportion of black 
or African–American and Asian patients, and most 
patients did not have cirrhosis, with only 12% of patients 
in the simeprevir group having a METAVIR score of F4 
(table 1).
When the QUEST-1 trial was initiated, the standard of 
care in HCV treatment was peginterferon alfa 2a plus 
ribavirin and therefore this standard was used as the 
comparator in the trial as the most appropriate control at 
the time. While the trial was in progress, the standard of 
care for HCV genotype 1 infection changed to treatment 
with direct-acting agents (namely, telaprevir and 
boceprevir) in combination with peginterferon alfa 2a plus 
ribavirin. The timeline did not allow for the comparator to 
represent this change in the standard of care. To address 
this limitation, a phase 3 non-inferiority trial to assess the 
eﬃ  cacy, safety, and tolerability of simeprevir versus 
telaprevir in combination with peginterferon alfa 2a plus 
ribavirin in patients with HCV infection who are null or 
partial responders to previous peginterferon alfa 2a plus 
ribavirin was initiated and is in progress (NCT01485991). 
Results from this trial will be available this year.
In conclusion, simeprevir, administered at 150 mg as a 
single pill once a day, in combination with peginterferon 
alfa 2a plus ribavirin enhances rates of sustained 
virological response compared with just peginterferon 
alfa 2a plus ribavirin, without exacerbating the side-eﬀ ect 
proﬁ le of peginterferon alfa 2a and ribavirin, and allows 
for a shortened duration of treatment in most patients. 
These results also establish a foundation for the 
assessment of simeprevir as a component of interferon-
free direct-acting agent regimens.38
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Panel: Research in context
Systematic review
The direct-acting antiviral agents that have been approved for the treatment of hepatitis C 
virus (HCV) infection have substantially improved sustained virological response (SVR) in 
infected patients; however, the associated dosing schedules are challenging and there is an 
increased incidence of treatment-related toxicity (eg, rash and anaemia). Therefore, an 
unmet clinical need exists for simpliﬁ ed, well tolerated regimens for patients infected with 
genotype 1 HCV.
Simeprevir is a one-pill, once-daily, oral HCV NS3/4A protease inhibitor approved in Japan, 
Canada, the USA, Russia, and Europe for the treatment of patients chronically infected 
with HCV. In the PILLAR19 and ASPIRE17 phase 2 trials, simeprevir at 150 mg once daily, 
administered to treatment-naive and treatment-experienced patients, respectively, was 
more eﬀ ective than were the lower doses tested (75 mg in PILLAR and 100 mg in ASPIRE), 
whereas extending simeprevir treatment beyond 12 weeks did not show a consistent 
beneﬁ t. Based on these results, the 150 mg for 12 weeks was selected for further 
investigation.
Interpretation
In the phase 3 QUEST-1 trial of the eﬃ  cacy, safety, and tolerability of simeprevir in 
combination with pegylated interferon (peginterferon) alfa-2a plus ribavirin (simeprevir 
group) in treatment-naive patients infected with genotype 1 HCV, SVR values at 12 weeks 
were signiﬁ cantly higher (irrespective of IL28B genotype, HCV genotype subtype, and 
METAVIR score), and lower for on-treatment failure and relapse, in the simeprevir group 
than in the placebo group. Most patients in the simeprevir group achieved high early 
response rates and qualiﬁ ed for shortened treatment duration. The safety and tolerability 
proﬁ les were favourable, with clinically manageable adverse events and signiﬁ cantly 
reduced severity of patient-reported fatigue and functioning impairments. Taken together, 
these results suggest that simeprevir represents an excellent candidate for inclusion in 
triple-therapy regimens in patients with HCV infection.
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